|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||15.31 - 15.85|
|52-week range||3.36 - 24.34|
|Beta (5Y monthly)||1.72|
|PE ratio (TTM)||28.11|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Organogenesis (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Good afternoon, ladies and gentlemen, and welcome to the second-quarter 2021 earnings conference call for Organogenesis Holdings, Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. During the second quarter, we reported revenue growth of 79% year over year to $123.2 million.
Organogenesis (ORGO) delivered earnings and revenue surprises of 114.29% and 16.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?